Table 3.
Adverse events
| PIB (n = 21) | CEI (n = 21) | P-value | |
|---|---|---|---|
| n (%) | n (%) | ||
| Adverse effects | |||
| Nausea, vomiting | 8(38.1) | 5(23.8) | 0.32 |
| Urinary retention | 2(9.5) | 3(14.3) | 0.63 |
| Feeling dizzy on standing up | 4(19.0) | 1(4.7) | 0.15 |
Adverse events
| PIB (n = 21) | CEI (n = 21) | P-value | |
|---|---|---|---|
| n (%) | n (%) | ||
| Adverse effects | |||
| Nausea, vomiting | 8(38.1) | 5(23.8) | 0.32 |
| Urinary retention | 2(9.5) | 3(14.3) | 0.63 |
| Feeling dizzy on standing up | 4(19.0) | 1(4.7) | 0.15 |